ArticlePediatric research2026
Albumin therapy in preterm infants after intestinal resection: a two-center retrospective cohort study.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlbumin infusion is commonly used in preterm infants following intestinal resection, but the optimal treatment duration remains unclear.
methodsThis two-center retrospective cohort study included 102 preterm infants who underwent intestinal resection in China between 2018 and 2024. Infants were classified as receiving short-course (≤5 days, n = 69) or long-course (>5 days, n = 33) albumin therapy. The primary outcome was 90-day all-cause mortality. Multivariable regression analyses modeled treatment duration as a continuous variable and adjusted for measured covariates; sensitivity and subgroup analyses were performed.
resultsNo statistically significant differences were observed in measured baseline characteristics between the groups. Crude 90-day mortality was numerically higher in the long-course group than in the short-course group (15.2% vs. 4.3%). When treatment duration was modeled continuously, the adjusted odds ratio for mortality was 1.36 per additional treatment day (95% CI, 0.98-1.97; P = 0.063). No statistically significant differences were detected in secondary outcomes or analyses using alternative duration thresholds.
conclusionsAmong preterm infants undergoing intestinal resection, no statistically significant differences in mortality or major postoperative outcomes were detected between treatment groups. However, clinician-determined treatment duration and residual confounding by indication preclude conclusions regarding equivalence or the clinical benefit of prolonged therapy. IMPACT: No statistically significant differences in mortality or major postoperative outcomes were detected between short-course (≤5 days) and long-course (>5 days) albumin therapy in preterm infants undergoing intestinal resection. Albumin treatment duration was determined by clinical status, and substantial residual confounding by indication cannot be excluded. These exploratory findings do not establish equivalence between treatment strategies and cannot determine whether prolonged albumin therapy provides clinical benefit.
Identifiers
42711562What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.